Lidds AB | Balance Sheet

Fiscal year is January-December. All values SEK Thousands.
2013
2014
2015
2016
2017
Cash & Short Term Investments
4,158.60
17,944.10
15,475.60
18,680.90
15,286.40
Total Accounts Receivable
4,830.80
985.00
421.00
1,620.10
1,244.40
Other Current Assets
-
-
332.10
508.90
-
Total Current Assets
8,989.40
18,929.10
16,228.80
20,809.90
16,530.80
Net Property, Plant & Equipment
24.20
-
-
-
-
Intangible Assets
67,772.20
79,761.40
86,117.10
100,200.80
114,279.80
Other Assets
-
-
-
0.20
0.20
Total Assets
76,785.80
98,690.50
102,345.90
121,010.70
130,810.60
Accounts Payable
1,050.50
1,700.60
1,337.40
6,638.10
2,103.90
Income Tax Payable
-
9.50
9.50
-
-
Other Current Liabilities
526.20
608.90
1,226.10
1,852.20
1,456.50
Total Current Liabilities
1,576.80
2,318.90
2,573.00
8,490.30
3,560.40
Total Liabilities
1,576.80
2,318.90
2,573.00
8,490.30
3,560.40
Common Equity (Total)
75,209.00
96,371.60
99,772.90
112,520.50
127,250.20
Total Shareholders' Equity
75,209.00
96,371.60
99,772.90
112,520.50
127,250.20
Total Equity
75,209.00
96,371.60
99,772.90
112,520.50
127,250.20
Liabilities & Shareholders' Equity
76,785.80
98,690.50
102,345.90
121,010.70
130,810.60

About Lidds AB

View Profile
Address
Virdings Allé 32B
Uppsala UP 754 50
Sweden
Employees -
Website http://www.lidds.se
Updated 09/14/2018
LIDDS AB operates as a pharmaceutical company. It engages in the research and development of pharmaceutical products. The company focuses on the development of treatment alternatives and hormonal therapy for prostate cancer.